Key facts
- This page summarizes Matthew Richard Moore's Form 4 filing for Arcutis Biotherapeutics, Inc. (ARQT).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 03 May 2024, 16:29.
Matthew Richard Moore - 01 May 2024 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)
- Reporting relationship
- SVP and Chief Business Officer
- Issuer ticker
- ARQT
- Reported as of
- 01 May 2024
- Net transaction value
- -$40,902
- SEC form
- 4
- Accepted by SEC
- 03 May 2024, 16:29:15 UTC
- Prior SEC filing
- 06 Mar 2024
- Next SEC filing
- 17 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Topper, Attorney-in-Fact for Matthew Richard Moore
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Matthew Richard Moore filed Form 4 for Arcutis Biotherapeutics, Inc. (ARQT) on 03 May 2024.
Change
- Previous filing in this sequence was filed on 06 Mar 2024.
- Current net transaction value: -$40,902.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ARQT
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +4,166
- Change %
- +2.9%
- Price
- $0.000000
- Shares after
- 150,186
- Date
- 01 May 2024
- Ownership
- Direct
- Footnotes
- F1, F2
ARQT
transaction
Common Stock
Sale
- Transaction value
- $40,902
- Shares
- -4,681
- Change %
- -3.1%
- Price
- $8.74
- Shares after
- 145,505
- Date
- 02 May 2024
- Ownership
- Direct
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
Represents Restricted Stock Units ("RSUs"), initial grant on February 22, 2024, that were subject to a performance-based vesting condition, that was determined to be satisfied on the Vesting Commencement Date, May 1, 2024.
Footnote F2
The RSUs will vest in twelve equal quarterly installments on the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Footnote F3
Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the RSUs, the shares were sold upon the vesting of the RSUs solely to cover applicable tax withholding.
Footnote F4
The transaction was executed in multiple trades in prices ranging from $8.47 to $9.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.